Viewing nowEmpagliflozin 25 mg Tablet (Empagliflozin)
Empagliflozin Amorphous 25mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202102078 · Approved 2021.03.05 · Insurance code 645907230
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar in adult patients with Type 2 diabetes. It can be administered as monotherapy or in combination with other diabetes medications such as metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors if blood sugar control is insufficient. Particularly, information regarding the prevention of cardiovascular events in Type 2 diabetes patients with cardiovascular disease should refer to professional guidelines. This medication is effective in improving blood sugar control and should be adjusted based on the individual patient's condition.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is required for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is required for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age and older. Initiation of this medicine is not recommended in patients 85 years of age and older because clinical experience is limited (see Precautions for Use, 4. General Precautions).
This medication should not be used in patients with a known allergy to the active ingredient or any of its components. It is not to be administered in patients with Type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired renal function, end-stage renal disease, or those on dialysis should not use this medication. It should not be used in patients with a genetic disorder that prevents lactose breakdown. Patients with mildly impaired renal function should use this medication with caution, and dosage adjustments or discontinuation may be necessary. Some patients with heart failure may require careful monitoring due to the lack of safety data. If taken with medications that pose a risk of hypoglycemia, such as insulin or sulfonylureas, dosage adjustments may be necessary to reduce the risk of hypoglycemia. Adverse effects may include hypoglycemia, urinary tract infections, genital infections, increased urination, dehydration, hypotension, and liver function abnormalities. Particularly, elderly patients or those at risk of fluid loss should be cautious of dehydration symptoms. This medication can cause a serious metabolic disorder called ketoacidosis, so if symptoms appear, immediate consultation with healthcare professionals is required. Due to potential liver damage, caution should be exercised if liver function abnormalities are present. Moreover, the risk of urinary and genital infections may be increased, so appropriate treatment is necessary if infection symptoms occur. This medication may affect lithium levels in the blood, so patients taking lithium should frequently monitor their blood levels. Pregnant women are advised not to use this medication, and it should also be avoided during breastfeeding. Safety and efficacy in pediatric patients under 18 years of age have not been established. There are no specific toxic symptoms reported in case of overdose, but appropriate medical intervention should be sought in the event of an overdose. This medication should be stored out of the reach of children and it is important not to transfer it to another container to maintain product quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.
A pale yellow, oval, biconvex, film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin Amorphous 25mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 10mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Empagliflozin Amorphous 25mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Empagliflozin Amorphous 10mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.